DOC apparently convinced Adage, Broadfin, Fidelity, etc. Not that your premise that the CEO convincing investors is valid. It's nonsense. Particularly for a biotech, where trial results and pre-clinical testing results are all that big investors need in order to evaluate a company.
News 
Market Data 
Discover 
